1st Total Artificial Heart Patient Discharged Home from Sentara Heart Hospital

63-Year-Old John Martino Looking Forward to Watching His 4 Grandchildren Grow Up

Tucson AZ USA, (PresseBox) - SynCardia Systems, Inc. (http://www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that on March 7, Sentara Heart Hospital in Norfolk, VA, discharged its first Total Artificial Heart patient home using the Freedom® portable driver.

"We expect Mr. Martino to be able to exercise, visit with friends and family, and lead a relatively normal life now that he is home," said cardiologist Dr. John Herre, medical director of the Sentara Advanced Heart Failure Program.

John Martino, a 63-year-old grandfather of four, is the second patient to be implanted with the Total Artificial Heart at Sentara and the first to be discharged from the hospital to wait for a matching donor heart at home. Sentara’s first patient, who received the Total Artificial Heart on Oct. 26, 2011, was successfully transplanted on Jan. 3, 2012.

"Our goal with Total Artificial Heart patients is to make them as strong and healthy as possible while awaiting a heart transplant," said Dr. Michael McGrath, a cardiac surgeon at Sentara Heart Hospital. "Replacing the diseased heart with the Total Artificial Heart helps keep the body functioning close to normal."

Mr. Martino was first diagnosed with hypertension in his early 20s when the draft board rejected him for service in Vietnam. Since then, his heart health has continued to decline - he's had his aortic valve replaced, double-bypass surgery and a pacemaker. In need of a heart transplant and running out of time, Mr. Martino's doctors decided his heart was too damaged for a left ventricular assist device (LVAD). On Jan. 19, he was implanted with the Total Artificial Heart as a bridge to transplant.

Less than a month later, Mr. Martino's condition had stabilized and on Feb. 20, he was switched from the 418-pound "Big Blue" hospital driver to the 13.5 pound Freedom portable driver, the world's first wearable power supply for the SynCardia Total Artificial Heart. He was discharged from the hospital on March 7.

"I'm thankful to be here," said Mr. Martino, who is looking forward to sitting in his lounge chair and sleeping in his own bed. "I have four grandchildren and that's what I live for now. I want to be able to see them grow up. So the longer I can be around to do that, I'm thankful."

The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

About the SynCardia temporary Total Artificial Heart:

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart. Similar to a heart transplant, the SynCardia temporary Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications.

Originally used as a permanent replacement heart, SynCardia’s Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 250 patient years of life. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles.

SynCardia Systems Inc

SynCardia Ranked #20 Among World’s 50 Most Innovative Companies:

In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the world’s 50 Most Innovative Companies for “giving mobility to artificial heart recipients.” Weighing 13.5 lbs, SynCardia’s Freedom® portable driver is the world’s first wearable driver designed to power the Total Artificial Heart both in side and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

For additional information, please visit: http://www.syncardia.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.